Search

Your search keyword '"Target therapies"' showing total 345 results

Search Constraints

Start Over You searched for: Descriptor "Target therapies" Remove constraint Descriptor: "Target therapies"
345 results on '"Target therapies"'

Search Results

151. Biological Treatments and Target Therapies for Pediatric Respiratory Medicine: Not Only Asthma.

152. Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.

153. New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials

154. Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer

155. Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma

156. Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America.

157. Pequeñas moléculas para el tratamiento de la LLC. Inhibidores de la BTK de segunda generación:: acalabrutinib

158. Delving into PARP inhibition from bench to bedside and back

159. Oligonucleotides-A Novel Promising Therapeutic Option for IBD

160. Pathogenesis of Peripheral T Cell Lymphoma

161. The Role of Circulating Biomarkers in the Oncological Management of Metastatic Renal Cell Carcinoma: Where Do We Stand Now?

162. [Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours].

163. Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study.

164. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations.

165. The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives.

166. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review.

167. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

168. Malignant transformation of sinonasal inverted papilloma and related genetic alterations: a systematic review

169. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies

170. A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study)

171. Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders

172. AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression.

173. Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer.

174. Delving into PARP inhibition from bench to bedside and back.

175. Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma.

176. Vulnerabilities in the tumor and microenvironment in follicular lymphoma.

177. Novel therapeutic approaches for cutaneous T cell lymphomas.

178. Targeting Galectin-1 by Aflibercept Strongly Enhances Its Antitumor Effect in Neuroendocrine Carcinomas.

179. From chemotherapy to target therapies associated with radiation in the treatment of NSCLC: a durable marriage?

180. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

181. Self-Triggered Apoptosis Enzyme Prodrug Therapy (STAEPT): Enhancing Targeted Therapies via Recurrent Bystander Killing Effect by Exploiting Caspase-Cleavable Linker

182. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.

183. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects.

185. Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment

186. New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia.

187. ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy.

188. Extracellular Vesicles as Biological Shuttles for Targeted Therapies.

189. Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

190. Prognostic role of

191. Seguridad y efectividad del nimotuzumab en los pacientes con tumores gliales malignos

192. PARP inhibition: A promising therapeutic target in ovarian cancer

193. Systemic therapy for the treatment of endometrial cancer.

194. The Importance of microRNAs in RAS Oncogenic Activation in Human Cancer.

195. An update on pathogenesis of psoriatic arthritis and potential therapeutic targets.

196. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.

197. Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance.

198. Oligonucleotides-A Novel Promising Therapeutic Option for IBD.

199. Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter.

200. Predictive factors of response to chemotherapy and/or target therapies in non small cell lung cancers

Catalog

Books, media, physical & digital resources